Spruce Biosciences, Inc.
SPRB
$60.95
$0.891.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -90.18% | -86.43% | -71.27% | -51.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -90.18% | -86.43% | -71.27% | -51.32% |
| Cost of Revenue | -70.65% | 2.26% | -10.66% | -2.29% | -6.10% |
| Gross Profit | 67.18% | -24.92% | -11.04% | -16.14% | -5.50% |
| SG&A Expenses | 2.37% | -6.81% | -3.66% | 3.43% | 15.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.14% | -0.31% | -8.93% | -1.03% | -1.64% |
| Operating Income | 49.04% | -14.44% | -6.69% | -12.80% | -8.00% |
| Income Before Tax | 26.53% | -21.44% | -12.13% | -18.61% | -10.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.53% | -21.44% | -12.13% | -18.61% | -10.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.53% | -21.44% | -12.13% | -18.61% | -10.68% |
| EBIT | 49.04% | -14.44% | -6.69% | -12.80% | -8.00% |
| EBITDA | 49.04% | -14.53% | -6.75% | -12.87% | -8.05% |
| EPS Basic | 44.61% | -17.56% | -8.59% | -15.15% | -1.50% |
| Normalized Basic EPS | 50.93% | -17.56% | -8.59% | -15.15% | -1.50% |
| EPS Diluted | 44.61% | -17.56% | -8.59% | -15.15% | -1.50% |
| Normalized Diluted EPS | 50.93% | -17.56% | -8.59% | -15.15% | -1.50% |
| Average Basic Shares Outstanding | 38.05% | 4.66% | 4.47% | 2.91% | 7.21% |
| Average Diluted Shares Outstanding | 38.05% | 4.66% | 4.47% | 2.91% | 7.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |